Total (n=257) | ||
N | %* | |
Demographic characteristics | ||
Age (years) | ||
Median (IQR) | 39 | (32–48) |
Age (years; categorised) | ||
≤34 | 85 | 33 |
35–44 | 80 | 31 |
≥45 | 92 | 36 |
Gender identity | ||
Male | 256 | 99 |
Transgender woman | 1 | 1 |
Self-declared ethnicity | ||
White | 217 | 84 |
Non-white | 40 | 16 |
Place of residency in the Netherlands | ||
Amsterdam | 159 | 62 |
Other | 98 | 38 |
Education level | ||
No college/University | 64 | 25 |
College/University | 193 | 75 |
Employment† | ||
Employed | 202 | 80 |
Unemployed | 9 | 4 |
Other (retired, volunteer, disabled, student) | 43 | 17 |
Net monthly income in €‡ | ||
≤1700 | 66 | 27 |
1701–2950 | 103 | 42 |
>2950 | 74 | 30 |
Living situation | ||
Alone | 141 | 55 |
With partner | 81 | 32 |
With parents/Flatmates | 35 | 14 |
Steady relationship§ | ||
No | 143 | 56 |
Yes | 111 | 44 |
Sexual preference¶ | ||
Exclusively homosexual | 199 | 78 |
Not exclusively homosexual | 57 | 22 |
Sexual behaviour | ||
Number of sex partners** | ||
Median (IQR) | 15 | (8–32) |
Number of condomless anal sex episodes with casual partners** | ||
Median (IQR) | 6 | (3–15) |
STIs†† | ||
No | 158 | 61 |
Yes | 99 | 39 |
Condomless anal sex with a casual partner (6 months prior to inclusion in AMPrEP) | ||
No | 13 | 5 |
Yes | 244 | 95 |
Mental health characteristics and drug use | ||
Sexual compulsivity scale | ||
Score <24 (no indication of sexual compulsivity) | 196 | 76 |
Score ≥24 (indication of sexual compulsivity) | 61 | 24 |
Chemsex‡‡ | ||
No | 147 | 58 |
Yes | 106 | 42 |
Depression or anxiety symptoms | ||
MHI-5 score ≥60 (no symptoms) | 212 | 82 |
MHI-5 score <60 (symptoms) | 45 | 18 |
Alcohol Use Disorder Identification Test§ | ||
Score <8 (no indication) | 186 | 73 |
Score ≥8 (indication) | 68 | 27 |
Drug Use Disorder Identification Test | ||
Score <8 (no indication) | 160 | 62 |
Score ≥8 (indication) | 97 | 38 |
Level of concern about acquiring HIV§§ | ||
Low | 41 | 16 |
Neutral to high | 216 | 84 |
Level of importance to prevent HIV§§ | ||
Very unimportant to important | 70 | 27 |
Very important | 187 | 73 |
Access to mobile application | ||
Standard app | 152 | 59 |
Extended app | 105 | 41 |
AMPrEP study visit attendance | ||
12 months | 246 | 96 |
24 months | 215 | 84 |
AMPrEP study, Amsterdam, 2015–2018.
*Percentages may not total 100 due to rounding.
†3 missing.
‡14 missing.
§3 missing.
¶1 missing.
**In the 3 months prior to inclusion into AMPrEP.
††Chlamydia, gonorrhoea and/or syphilis within 6 months prior to inclusion into AMPrEP.
‡‡Use of γ-hydroxybutyrate, γ-butyrolactone, methamphetamine or mephedrone prior to or during sex in the 3 months prior to inclusion into AMPrEP, 4 missing.
§§Scale 1–7, dichotomised.
AMPrEP, Amsterdam PrEP demonstration project; MHI5, Mental Health Inventory-5; PrEP, pre-exposure prophylaxis; RCT, randomised clinical trial.